Tonix Pharmaceuticals has reported positive topline outcomes from its Phase I single ascending dose study of its ...

Eledon Pharmaceuticals (ELDN) announced that tegoprubart, the company’s investigational anti-CD40L antibody, was used as a key component of the ...

Genesis announced that it has completed its second successful human transplant with a genetically engineered pig kidney, with ...

Investors interested in arranging a meeting with the Company’s management during the conference can register on the BIO CEO & Investor Conference website here.

The two patients received the treatment as part of a UChicago Medicine pilot study focusing on the use of Eledon's anti CD40 ligand (CD40L) antibody tegoprubart (formerly AT-1501) as an ...

Tonix Pharmaceuticals (NASDAQ: TNXP) released selected preliminary financial results for 2024, reporting approximately $98.8 million in cash and cas ...

The three-signal paradigm tries to capture how the innate immune system instructs adaptive immune responses in three well-defined actions: (1) presentation of antigenic peptides in the context of MHC ...

CD154 is the ligand for the receptor CD40. This ligand–receptor pair mediates endothelial and antigen-presenting cell activation, and facilitates the interaction of these cells with T cells and ...